-
WHEN ADHERENCE ESTIMATES DIFFER: THE IMPACT OF DATA SOURCE AND GAP HANDLING IN REAL-WORLD MEDICATION USE ASSESSMENT
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS OF LAZERTINIB-AMIVANTAMAB COMPARED TO OSIMERTINIB FOR NON-SMALL CELL LUNG CANCER: A 5-YEAR PARTITIONED SURVIVAL MODEL
Mar 18, 2026, 21:38 PM -
INCORPORATING SPILLOVER EFFECTS IN COST-EFFECTIVENESS ANALYSIS: A CASE STUDY FOR FIRST LINE TREATMENT OF METASTATIC (STAGE IV) NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)
Mar 18, 2026, 21:38 PM -
EVALUATING THE IMPACT OF THE INFLATION REDUCTION ACT OUT-OF-POCKET CAPS ON PATIENT ASSISTANCE FUNDS EFFICIENCY AND COVERAGE EXPANSION
Mar 18, 2026, 21:38 PM -
AI-ASSISTED APPROACHES FOR DEFINING LINES OF THERAPY IN ONCOLOGY REAL-WORLD DATA: AN EXPLORATORY ANALYSIS IN CHRONIC LYMPHOCYTIC LEUKEMIA
Mar 18, 2026, 21:38 PM -
HEALTHCARE RESOURCE UTILIZATION AND COSTS OF DIABETES MELLITUS: A RETROSPECTIVE REAL-WORLD COST-OF-ILLNESS ANALYSIS IN BRAZIL
Mar 18, 2026, 21:38 PM -
MACHINE LEARNING EVALUATION OF RACIAL AND ETHNIC INCLUSION UNDER ALTERNATIVE COST-BASED APPROACHES TO MEDICARE MEDICATION THERAPY MANAGEMENT ELIGIBILITY
Mar 18, 2026, 21:38 PM -
USE OF REAL-WORLD EVIDENCE ON US BRANDED HCP DRUG WEBSITES: AN AI-ENABLED CONTENT ANALYSIS
Mar 18, 2026, 21:38 PM -
TEMPORAL TRENDS AND DETERMINANTS OF AORTIC VALVE REPLACEMENT IN PATIENTS WITH ASYMPTOMATIC SEVERE AORTIC STENOSIS
Mar 18, 2026, 21:38 PM -
COST COMPARISON OF ATEZOLIZUMAB IN CANADA FOR THE FIRST-LINE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER PATIENTS WITH HIGH PROGRAMMED DEATH-LIGAND 1 EXPRESSION
Mar 18, 2026, 21:38 PM -
COULD OPERATING-ROOM TIME DIFFERENCES FOR LITHOTRIPSY BE AN INDICATOR OF HEALTHCARE ACCESS?
Mar 18, 2026, 21:38 PM -
DISTANCE FROM HEALTH CARE FACILITY AND OTHER VARIABLES IMPACT TIME TO CELIAC DISEASE DIAGNOSIS
Mar 18, 2026, 21:38 PM -
DO DATA SOURCES MATTER? COMPARING MARKET COST AND PAYER COST APPROACHES TO CALCULATING MEDICAL SPENDING MEASURES IN REAL-WORLD DATA
Mar 18, 2026, 21:38 PM -
ESTIMATING THE HEALTH OPPORTUNITY COST OF PUBLIC HEALTH EXPENDITURE IN KAZAKHSTAN: EMPIRICAL SUPPLY-SIDE COST-EFFECTIVENESS THRESHOLDS
Mar 18, 2026, 21:38 PM -
USE OF REAL-TIME AI-ASSISTED LIVING SYSTEMATIC LITERATURE REVIEW (REAL-SLR) IN PROSTATE CANCER (PC) ENABLES ON-DEMAND ACCESS TO PIVOTAL CLINICAL TRIAL EVIDENCE
Mar 18, 2026, 21:38 PM -
INCREASED RISK OF DIABETIC KETOACIDOSIS IN ADULTS WITH DELAYED DIAGNOSIS OF TYPE 1 DIABETES
Mar 18, 2026, 21:38 PM -
PROBABILISTIC LINKING OF CLAIMS AND ELECTRONIC HEALTH RECORD (EHR) ENCOUNTERS USING THE FELLEGI-SUNTER STATISTICAL FRAMEWORK
Mar 18, 2026, 21:38 PM -
QUANTIFYING THE OPPORTUNITY: THE ECONOMIC AND COMMERCIAL CASE FOR ALS TREATMENT INNOVATION
Mar 18, 2026, 21:38 PM -
ENABLING HEALTH TECHNOLOGY ASSESSMENT (HTA) TA READINESS THROUGH REAL-TIME AI-ASSISTED LIVING SYSTEMATIC LITERATURE REVIEWS (REAL-SLR): A BREAST CANCER (BCA) CASE STUDY
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS OF SUBCUTANEOUS MOSUNETUZUMAB PLUS POLATUZUMAB VEDOTIN VERSUS RITUXIMAB PLUS GEMCITABINE AND OXALIPLATIN FOR UNITED STATES (US) PATIENTS WITH AUTOLOGOUS STEM CELL TRANSPLANT-INELIGIBLE RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA
Mar 18, 2026, 21:38 PM
